A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Marginal Zone Lymphoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a Phase III randomized, double-blind, placebo controlled, multicenter.Masking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04212013
- Collaborators
- Pharmacyclics LLC.
- Investigators
- Principal Investigator: Ariela Noy, MD Memorial Sloan Kettering Cancer Center
Get Well Soon